Company Consolidates Resources to Princeton, New Jersey Headquarters
PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it recently appointed Christopher P. Schnittker, CPA as its new Vice President of Administration and Controller. In this role, Mr. Schnittker will oversee the Accounting, Human Resources, and Administrative functions, as well as serve as the Company's Principal Accounting Officer for SEC reporting purposes.
Mr. Schnittker comes to DOR with more than 18 years of financial management experience primarily in publicly held life science companies. Prior to joining DOR, he served in the senior financial roles for VioQuest Pharmaceuticals Inc., Micromet Inc., Cytogen Corporation and Genaera Corporation, all publicly traded, R&D-focused companies in the biotechnology and specialty pharmaceuticals arenas. Mr. Schnittker also held management positions in accounting, reporting and auditing at GSI Commerce, Rhone-Poulenc Rorer (now part of Sanofi-Aventis), and PricewaterhouseCoopers. He received his Bachelor's degree in Economics and Business with a concentration in Accounting from Lafayette College and is a Certified Public Accountant currently licensed in the State of New Jersey.
'I am very excited to be joining DOR at this point in its development. The remainder of 2009 promises to be a significant step forward with the initiation of the Company's confirmatory Phase 3 trial for orBec(R), as well as the achievement of important development milestones in other key programs,' stated Mr. Schnittker.
'We are very pleased to welcome Christopher to the DOR team,' said Evan Myrianthopoulos, Chief Financial Officer of DOR. 'His experience with development stage and commercialized biotech and pharmaceutical companies will serve us well in preparation for our increased clinical trial activities in the latter half of this year and going forward into 2010. Part of the rationale for our move to New Jersey was to be able to draw on the deep life science talent pool exemplified by Christopher that exists in the state and surrounding areas. Christopher's addition marks the next phase of our consolidation and growth as a late-stage Princeton, New Jersey-based biotechnology company.'
As expected and pursuant to the Company's plans to consolidate operations in New Jersey, Mr. Schnittker will take over the responsibilities of James Clavijo, CPA in the Controller function. Mr.
